help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pang, P. K.
Right arrow Articles by Kenny, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pang, P. K.
Right arrow Articles by Kenny, A. D.

Endocrinology, Vol 112, 284-289, Copyright © 1983 by Endocrine Society


ARTICLES

Structure activity relationship of parathyroid hormone: separation of the hypotensive and the hypercalcemic properties

PK Pang, MC Yang, HT Keutmann and AD Kenny

The present study was conducted to show that the hypercalcemic and the vascular relaxing activities of PTH are two separable properties. During the hypotensive action of the synthetic fragment bovine (b) PTH- (1-34), plasma calcium levels were not significantly changed. Mild oxidation with hydrogen peroxide abolished the hypotensive and hypercalcemic actions of bPTH-(1-84). However, the same treatment on bPTH-(1-34) abolished only the hypotensive and not the hypercalcemic action. Analysis of the amino acid composition revealed only the oxidation of the methionines to methionine sulfoxides. The other amino acids remained unchanged. In addition, the analog with methionines replaced by norleucine, [Nle8,Nle18,Tyr34]bPTH-(1-34), was active in all the vascular assays, and these activities were unaffected by hydrogen peroxide treatment of the molecule. Perhaps the methionine sulfoxides in the hydrogen peroxide-treated bPTH-(1-34) affected the changes of the molecule in such a manner that the part of the molecule for the vascular action but not that for the hypercalcemic action was no longer accessible to the receptors of the target organs. The hypotensive pentapeptide, bPTH-(24-28), was not active in the hypercalcemic assay. All these data are consistent with our hypothesis that the vascular relaxing and the hypercalcemic actions of PTH are two separate properties of the molecule.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
G. Barletta, M. L. De Feo, R. Del Bene, C. Lazzeri, S. Vecchiarino, G. La Villa, M. L. Brandi, and F. Franchi
Cardiovascular Effects of Parathyroid Hormone: A Study in Healthy Subjects and Normotensive Patients with Mild Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1815 - 1821.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
S. Yamamoto, I. Morimoto, K. Zeki, Y. Ueta, H. Yamashita, H. Kannan, and S. Eto
Centrally Administered Parathyroid Hormone (PTH)-Related Protein(1-34) But Not PTH(1-34) Stimulates Arginine-Vasopressin Secretion and Its Messenger Ribonucleic Acid Expression in Supraoptic Nucleus of the Conscious Rats
Endocrinology, January 1, 1998; 139(1): 383 - 388.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Yamamoto, I. Morimoto, N. Yanagihara, K. Zeki, T. Fujihira, F. Izumi, H. Yamashita, and S. Eto
Parathyroid Hormone-Related Peptide-(1-34) [PTHrP- (1-34)] Induces Vasopressin Release from the Rat Supraoptic Nucleus in Vitro through a Novel Receptor Distinct from a Type I or Type II PTH/PTHrP Receptor
Endocrinology, May 1, 1997; 138(5): 2066 - 2072.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society